201 related articles for article (PubMed ID: 23328666)
1. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
[TBL] [Abstract][Full Text] [Related]
2. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
[TBL] [Abstract][Full Text] [Related]
4. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.
Grymula K; Tarnowski M; Wysoczynski M; Drukala J; Barr FG; Ratajczak J; Kucia M; Ratajczak MZ
Int J Cancer; 2010 Dec; 127(11):2554-68. PubMed ID: 20162608
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.
Lukasiewicz E; Miekus K; Kijowski J; Drabik G; Wilusz M; Bobis-Wozowicz S; Majka M
Folia Histochem Cytobiol; 2009 Jan; 47(3):485-9. PubMed ID: 20164036
[TBL] [Abstract][Full Text] [Related]
6. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
Saini M; Verma A; Mathew SJ
Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
[TBL] [Abstract][Full Text] [Related]
7. The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
Jaaks P; D'Alessandro V; Grob N; Büel S; Hajdin K; Schäfer BW; Bernasconi M
PLoS One; 2016; 11(8):e0161396. PubMed ID: 27548722
[TBL] [Abstract][Full Text] [Related]
8. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas.
Tarnowski M; Schneider G; Amann G; Clark G; Houghton P; Barr FG; Kenner L; Ratajczak MZ; Kucia M
Int J Oncol; 2012 Sep; 41(3):995-1004. PubMed ID: 22752028
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.
Strahm B; Durbin AD; Sexsmith E; Malkin D
Clin Exp Metastasis; 2008; 25(1):1-10. PubMed ID: 17768666
[TBL] [Abstract][Full Text] [Related]
12. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
13. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.
Libura J; Drukala J; Majka M; Tomescu O; Navenot JM; Kucia M; Marquez L; Peiper SC; Barr FG; Janowska-Wieczorek A; Ratajczak MZ
Blood; 2002 Oct; 100(7):2597-606. PubMed ID: 12239174
[TBL] [Abstract][Full Text] [Related]
14. HGF-induced PKCζ activation increases functional CXCR4 expression in human breast cancer cells.
Huang S; Ouyang N; Lin L; Chen L; Wu W; Su F; Yao Y; Yao H
PLoS One; 2012; 7(1):e29124. PubMed ID: 22242160
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.
Tarnowski M; Grymula K; Liu R; Tarnowska J; Drukala J; Ratajczak J; Mitchell RA; Ratajczak MZ; Kucia M
Mol Cancer Res; 2010 Oct; 8(10):1328-43. PubMed ID: 20861157
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
17. Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress.
Szewczyk B; Skrzypek K; Majka M
Curr Drug Targets; 2017; 18(1):98-107. PubMed ID: 26674534
[TBL] [Abstract][Full Text] [Related]
18. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
[TBL] [Abstract][Full Text] [Related]
19. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases.
Son BR; Marquez-Curtis LA; Kucia M; Wysoczynski M; Turner AR; Ratajczak J; Ratajczak MZ; Janowska-Wieczorek A
Stem Cells; 2006 May; 24(5):1254-64. PubMed ID: 16410389
[TBL] [Abstract][Full Text] [Related]
20. HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.
Rø TB; Holien T; Fagerli UM; Hov H; Misund K; Waage A; Sundan A; Holt RU; Børset M
Exp Hematol; 2013 Jul; 41(7):646-55. PubMed ID: 23499762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
